News around the
Sonablate community

In Sonablate News



Charlotte, NC (EIN Newswire) [January 22, 2021] – SonaCare  Medical, the leading developer and manufacturer of high intensity  focused ultrasound (HIFU) technologies, is pleased to announce a  partnership with the Mayo Clinic. SonaCare will partner with the Mayo  Clinic to launch the first Sonablate HIFU Center of Excellence in  Rochester, MN. In addition to the purchase of a Sonablate system, the  Mayo Clinic will look to educate other providers on the use of Sonablate  HIFU and the development of prostate focal therapy programs.  It is  anticipated that the Mayo Clinic will be contributing to ongoing HIFU  research and publications which are important in furthering the adoption  and acceptance of prostate focal therapy. . The Mayo Clinic is a  nonprofit American academic medical center focused on integrated  healthcare, education, and research and a world-renowned leader in  oncologic care. “We are excited to add Sonablate HIFU to our focal  therapy offerings at Mayo Clinic. No one ablation technology is right  for all lesions and prostates so having multiple options available is  incredibly important to be able offer focal therapy to all qualified  patients. Sonablate HIFU is our least invasive offering yet and will  become an important part of our focal therapy program” said, Dr. Derek  Lomas, Assistant Professor of Urology at the Mayo Clinic.

Mr. Brad Snow, SonaCare Medical CEO, said, “We are thrilled to  announce this partnership with such a renowned institution as the Mayo  Clinic. We look forward to collaborating with Mayo Clinic in becoming a  world class Sonablate Center of Excellence and serve as an example for  future centers throughout the world.”Since Sonablate® received FDA clearance on October 9, 2015, many  thousands of patients have had a Sonablate HIFU prostate procedure  across the 60+ locations in the U.S., including top-tier academic  institutions in California, Indiana, Oklahoma, Maryland, New York,  Arizona and Texas.  Over 70 U.S. physicians now offer HIFU prostate  tissue ablation to their patients as a minimally invasive alternative to  surgery or radiation.

Sonablate® has 501(K) clearance in the U.S. and is indicated for the  transrectal high intensity focused ultrasound (HIFU) ablation of  prostate tissue. Caution: Federal (USA) law restricts this device to  sale by or on the order of a physician.

SonaCare Medical is a world leader in minimally invasive focused ultrasound technologies. SonaCare Medical is committed to developing focused ultrasound related technologies that support precise and innovative procedures for the treatment of a range of medical  conditions. SonaCare Medical, with its subsidiary Focus Surgery, Inc., designs and manufactures medical devices, including the following:  Sonablate®, which has 501(K) clearance in the U.S.; Sonablate®500, which  has CE Marking and has obtained regulatory authorization in more than  50 countries outside the U.S., Sonatherm® laparoscopic HIFU surgical  ablation system, which has 510(K) clearance in the U.S., has CE Marking  and has obtained regulatory authorization in more than 30 countries  outside the U.S.For additional information, visit

SonaCare Medical, LLC
Karen Cornett (704) 805-1885

The Company's  forward-looking statements are based on management's current  expectations and assumptions regarding the Company's business and  performance, the economy and other future conditions and forecasts of  future events, circumstances and results. As with any projection or  forecast, forward-looking statements are inherently susceptible to  uncertainty and changes in circumstances. The Company's actual results  may vary materially from those expressed or implied in its  forward-looking statements. Any forward-looking statement made by the  Company speaks only as of the date on which it is made. The Company is  under no obligation to, and expressly disclaims any obligation to,  update or alter its forward-looking statements, whether as a result of  new information, subsequent events or other factors.